ReviewEuropean respiratory review : an official journal of the European Respiratory Society2015
Pharmacological therapy for patients with chronic thromboembolic pulmonary hypertension.
Review in European respiratory review : an official journal of the European Respiratory Society, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 1 synthesis or guideline pooled it, 59 citations in OpenAlex.
- Guanylate cyclase stimulators for pulmonary hypertension.The Cochrane database of systematic reviews · 2016Pooled it
- Selexipag for the treatment of chronic thromboembolic pulmonary hypertension.The European respiratory journal · 2022Trial
- The Surgical Management of Chronic Thromboembolic Pulmonary Hypertension.Journal of clinical medicine · 2025Review
- Unraveling the Complex Relationship-Atrial Fibrillation and Pulmonary Hypertension.Current cardiology reports · 2024Review
- Observational
- Chronic Thromboembolic Pulmonary Hypertension: the therapeutic assessment.Frontiers in cardiovascular medicine · 2024Review
- Clinical evaluation of code-based algorithms to identify patients with pulmonary arterial hypertension in healthcare databases.Pulmonary circulation · 2024Article
- Clinical-radiological-pathological correlation in chronic thromboembolic pulmonary hypertension.European respiratory review : an official journal of the European Respiratory Society · 2023Article
- Central versus Peripheral CTEPH-Clinical and Hemodynamic Specifications.Medicina (Kaunas, Lithuania) · 2022Article
- Chronic Thromboembolic Pulmonary Hypertension: An Observational Study.Medicina (Kaunas, Lithuania) · 2022Observational
- Surgical Management of Chronic Thromboembolic Pulmonary Hypertension.Cardiology clinics · 2022Review
- Chronic Thromboembolic Pulmonary Hypertension: An Update.Diagnostics (Basel, Switzerland) · 2022Review
- Epidemiology of chronic thromboembolic pulmonary hypertension (CTEPH) in the Czech Republic.Pulmonary circulation · 2022Article
- Endogenous Hemoprotein-Dependent Signaling Pathways of Nitric Oxide and Nitrite.Inorganic chemistry · 2021Review
- Chronic Thromboembolic Pulmonary Hypertension Medical Management.Methodist DeBakey cardiovascular journal · 2021Article
- Soluble Guanylate Cyclase Stimulators and Activators.Handbook of experimental pharmacology · 2021Article
- Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension: State of the art.World journal of clinical cases · 2020Review
- Advances in targeted therapy for chronic thromboembolic pulmonary hypertension.Heart failure reviews · 2019Review
- ＜Editors' Choice＞ Pulmonary Hypertension: Diagnosis, Management, and Treatment.Nagoya journal of medical science · 2019Review
- Chronic thromboembolic pulmonary hypertension: emerging endovascular therapy.Cardiovascular diagnosis and therapy · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare but life-threatening disease resulting from unresolved thromboembolic obstructions. Pulmonary endarterectomy (PEA) surgery is the gold-standard treatment as it is potentially curative; however, not all patients are deemed operable and up to one-third have persistent or recurrent CTEPH after the procedure. Pulmonary arterial hypertension (PAH) and CTEPH have similar clinical presentations and histopathological features, so agents shown to be effective in PAH have often been prescribed to patients with CTEPH in the absence of proven therapies. However, clinical evidence for this strategy is not compelling. A number of small uncontrolled trials have investigated endothelin receptor antagonists, prostacyclin analogues and phosphodiesterase type 5 inhibitors in CTEPH with mixed results, and a phase III study of the endothelin receptor antagonist bosentan met only one of its two co-primary end-points. Recently, however, the soluble guanylate cyclase stimulator, riociguat, was approved in the USA and Europe for the treatment of inoperable or persistent/recurrent CTEPH following positive results from the phase III CHEST study (Chronic Thromboembolic Pulmonary Hypertension Soluble Guanylate Cyclase-Stimulator Trial). This article reviews the current evidence for the use of pharmacological therapies in CTEPH.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.